High quality Raw Powder Rimonabant CAS 105-41-9 for Weight Loss

Quick Details:

**********************************************************************************************************************

Description:
Rimonabant / Acomplia selectively blocks the CB1 receptors that are present in the brain and other peripheral organs important in fat/lipid and glucose metabolism, including muscle, gastrointestinal tract, liver and adipose tissue. Basically, it switches off those brain circuits that are responsible for making people hungry while smoking . Acomplia, along with CB1 receptors, reduces the EC system's over-activity. 
 
Rimonabant / Acomplia is said to have reduced the overall body fat by 10% in one out of three users. Also, it is reported that those users did not gain back more than a kilo over the next two years if the patients remained on Rimonabant. Rimonabant was recommended for those with a BMI of 30 or greater, who were considered obese, and is most successful when combined with exercise and a proper diet.
**********************************************************************************************************************

**********************************************************************************************************************

Function :
 
Rimonabant / Acomplia is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. 
 
Rimonabant / Acomplia,Developed by Sanofi-Aventis, Acomplia (Rimonabant) is a selective CB1 receptor antagonist. In other words, Rimonabant is intended to promote weight loss by reducing the total number of calories an individual consumes on a daily basis.
 
Rimonabant / Acomplia works by blocking endogenous from binding to neuronal CB1 receptors. The activation of these receptors by endogenous , such as anadamide, increases an individuals appetite. By blocking the activation of the receptors, appetite suppression may occur.
**********************************************************************************************************************
 
Dosage:

It is expected that the usual dose of  rimonabant will be 20 mg once daily before breakfast. No dosage adjustment is recommended for the elderly, but this agent should be used with caution in patients older than 75 years of age.

Although rimonabant can be used in patients with mild hepatic impairment, caution is advised in patients with moderate impairment. This medication is not recommended for those with severe hepatic impairment.

Rimonabant may be used cautiously in patients with mild-to-moderate renal impairment, but it is not recommended for patients who are severely renally impaired.

There are no data supporting the use of rimonabant in pediatric populations.

Rimonabant should not be given to patients with a known hypersensitivity to the agent or any compound found in the tablet formulation.

The drug is contraindicated in lactat-ing women and is not recommended for use in women who are pregnant.


 
**********************************************************************************************************************    
Applications
 
Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.
 
Rimonabant works by blocking endogenous cannabinoid from binding to neuronal CB1 receptors. The activation of these receptors by endogenous cannabinoids, such as anadamide, increases an individuals appetite. By blocking the activation of the receptors, appetite suppression may occur.
*********************************************************************************************************************    
Specification

 
**********************************************************************************************************************

How to procede a order:
1. Name what your need (which product,quantity)
2. Full payment would be done once we come to an agreement on all details .
3. Parcel would be shipped out upon receipt of payment .
4. Info about parcel would be offered (Photo , tracking number)
5. Finally you would get the parcel in 3~15 days.

**********************************************************************************************************************

Fat Loss Products

Our Service:

Payment method: Paypal, Western Union, Moneygram, TT.

Shipping method: EUB, DHL, EMS or by SEA

Delivery time: within 3 days after payment

High quality Raw Powder Rimonabant CAS 105-41-9 for Weight Loss

Quick Details:

**********************************************************************************************************************

Description:
Rimonabant / Acomplia selectively blocks the CB1 receptors that are present in the brain and other peripheral organs important in fat/lipid and glucose metabolism, including muscle, gastrointestinal tract, liver and adipose tissue. Basically, it switches off those brain circuits that are responsible for making people hungry while smoking . Acomplia, along with CB1 receptors, reduces the EC system's over-activity. 
 
Rimonabant / Acomplia is said to have reduced the overall body fat by 10% in one out of three users. Also, it is reported that those users did not gain back more than a kilo over the next two years if the patients remained on Rimonabant. Rimonabant was recommended for those with a BMI of 30 or greater, who were considered obese, and is most successful when combined with exercise and a proper diet.
**********************************************************************************************************************

**********************************************************************************************************************

Function :
 
Rimonabant / Acomplia is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. 
 
Rimonabant / Acomplia,Developed by Sanofi-Aventis, Acomplia (Rimonabant) is a selective CB1 receptor antagonist. In other words, Rimonabant is intended to promote weight loss by reducing the total number of calories an individual consumes on a daily basis.
 
Rimonabant / Acomplia works by blocking endogenous from binding to neuronal CB1 receptors. The activation of these receptors by endogenous , such as anadamide, increases an individuals appetite. By blocking the activation of the receptors, appetite suppression may occur.
**********************************************************************************************************************
 
Dosage:

It is expected that the usual dose of  rimonabant will be 20 mg once daily before breakfast. No dosage adjustment is recommended for the elderly, but this agent should be used with caution in patients older than 75 years of age.

Although rimonabant can be used in patients with mild hepatic impairment, caution is advised in patients with moderate impairment. This medication is not recommended for those with severe hepatic impairment.

Rimonabant may be used cautiously in patients with mild-to-moderate renal impairment, but it is not recommended for patients who are severely renally impaired.

There are no data supporting the use of rimonabant in pediatric populations.

Rimonabant should not be given to patients with a known hypersensitivity to the agent or any compound found in the tablet formulation.

The drug is contraindicated in lactat-ing women and is not recommended for use in women who are pregnant.


 
**********************************************************************************************************************    
Applications
 
Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.
 
Rimonabant works by blocking endogenous cannabinoid from binding to neuronal CB1 receptors. The activation of these receptors by endogenous cannabinoids, such as anadamide, increases an individuals appetite. By blocking the activation of the receptors, appetite suppression may occur.
*********************************************************************************************************************    
Specification

 
**********************************************************************************************************************

How to procede a order:
1. Name what your need (which product,quantity)
2. Full payment would be done once we come to an agreement on all details .
3. Parcel would be shipped out upon receipt of payment .
4. Info about parcel would be offered (Photo , tracking number)
5. Finally you would get the parcel in 3~15 days.

**********************************************************************************************************************

Fat Loss Products

Our Service:

Payment method: Paypal, Western Union, Moneygram, TT.

Shipping method: EUB, DHL, EMS or by SEA

Delivery time: within 3 days after payment

Volsen owns a professional custom synthesis department, with more than 15 senior scientific research chemical personnels who have a graduate degree or above. We also have an independent scientific management system. Our company integrates years of production experiences and talent reserves that forms a strong R&D production capacity, furthermore we could undertake various chemicals customizations from kg to ton relying on the existing production base and equipment.

With the accumulated strong expertise,and experiences of developments,we have developed the products with good quality and also manufactured the intermediates for multi-national pharmaceutical company.

R&D Pharmaceutical

R&D Pharmaceutical, Research And Development Pharmaceutical, Bulk Drug Development

Taizhou Volsen Chemical Co., Ltd. , http://www.volsenchem.com